{"entity":{"id":"nct04879043","kind":"trial","name":"Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma","aka":[],"tldr":"A phase 1/2 trial of HDP-101 in multiple myeloma, run by Heidelberg Pharma AG, now recruiting.","summary":"Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT04879043 by Heidelberg Pharma AG, with 78 participants planned, started 2022-02-07 and due to reach its primary completion in 2028-03. Interventions recorded: HDP-101.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04879043","url":"https://clinicaltrials.gov/study/NCT04879043"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["heidelberg-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04879043","phase":"1/2","setting":"A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma","sponsor":"Heidelberg Pharma AG","started":"2022-02-07","startedType":"actual","enrolled":78,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04879043/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"company":[{"id":"heidelberg-pharma","kind":"company","name":"Heidelberg Pharma","route":"/companies/heidelberg-pharma/"}]}}